

CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs

Component
Investment and innovation


Investment
Mobilizing Agendas/Alliances for Reindustrialization



INVESTMENT PERIOD
01-01-2023 a 30-06-2026



TOTAL PROJECT VALUE
34.696.828,85€



CInTech: Technological Hub for Innovation, Translation and Industrialization of Complex Injectable Drugs

The CInTech aims to create and empower the 1st Technological Hub for Innovation, Translation, and Industrialization dedicated to complex injectable drugs: innovative technological platforms capable of incorporating different therapeutic agents for oncology (small molecules, peptides, nucleic acids).

It will be a unique Hub comprising 3 Centers: A laboratory-scale R&I center dedicated to stimulating translation of knowledge and technology; a development, process engineering and scale-up center, focused on analytical development and prototyping; and a highly specialized GMP Center, capable of manufacturing complex injectable, developed by the consortium or by third parties.

CInTech will be a structuring and mobilizing project, with a high impact on the economy and scientific innovation in Portugal, promoting synergistic cooperation between SMEs, non-SMEs, and the National Scientific and Technological System (SCTN), and the creation of a highly differentiated portfolio, which, in addition to the benefits for the patient, represents a contribution to the exports of high-technology tradable goods and services.

Main objectives:

CInTech consortium is a strategic and synergistic alliance that brings together Portuguese industries in the pharmaceutical sector (Bluepharma - Indústria Farmacêutica, S.A.), intralogistics (JPM - Automação e Equipamentos Industriais, S.A.), engineering (JointSteel - Process Technologies, S.A.), and biotechnology (Biotrend - Inovação e Engenharia em Biotecnologia, S.A.), along with some of the most dynamic and innovative centers (University of Coimbra and the Iberian International Nanotechnology Laboratory). The consortium aims to deliver a total of seven products, processes, and/or services (PPS):

- PPS1 (product) – New polymeric excipient with potential to be used in complex injectable formulations and patentable;
- PPS2 (process, service) – New unit for Design, Production and Analytical Control of nucleic acids;
- PPS3 (product) – Novel lipid technological platform (LNP) for delivery of therapeutic agents;
- PPS4 (product) – Novel polymer technological platform (PNP) for delivery of therapeutic agents;
- PPS5 (product) – New set of customized process equipment for the pharmaceutical industry;
- PPS6 (product) – New digital solution for process management and monitoring;
- PPS7 (process, service) – Construction and empowerment of dedicated centers for development and GMP manufacturing of complex injectables;
- PPS 8 (process, service) – Specialized Service Unit for the Development and Characterization of Complex Injectables (with focus on lyophilized products);
- PPS 9 (process, service) – Unit for Automated Production and Purification of mRNA.

Total project value

34.696.828,85€

Start date

01.01.2023

End date

30.06.2026

Dimension

Resilience

Component

Investment and innovation

Investment

Mobilizing Agendas /Alliances for Reindustrialization

Project Code

C644865576-00000005